Merck KGaA advances anti-GD2 ADC toward clinic for solid tumors

June 4, 2024

Merck KGaA has announced it is advancing M-3554, a potential first-in-class anti-GD2 antibody-drug conjugate (ADC), toward the clinic. M-3554 links an exatecan payload with an anti-GD2 antibody.

BioWorld Science Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

mRNA-based vaccine is immunogenic, protective in Lyme disease

BioWorld Science

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Alzheon’s lead candidate misses a phase III in early Alzheimer’s

BioWorld

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long...